(Q38788562)

6 September 2017

Evaluating the safety of β-interferons in MS: A series of nested case-control studies (English)

1 reference

Jan Willem Cohen Tervaert

6 September 2017

0 references

4

object named as

Jan Willem Cohen Tervaert

1 reference

6 September 2017

9

Mia L van der Kop

1 reference

6 September 2017

Hilda J I de Jong

1

1 reference

6 September 2017

Elaine Kingwell

2

1 reference

6 September 2017

Afsaneh Shirani

3

1 reference

6 September 2017

Raymond Hupperts

5

1 reference

6 September 2017

Yinshan Zhao

6

1 reference

6 September 2017

Feng Zhu

7

1 reference

6 September 2017

Charity Evans

8

1 reference

6 September 2017

Anthony Traboulsee

10

1 reference

6 September 2017

Paul Gustafson

11

1 reference

6 September 2017

John Petkau

12

1 reference

6 September 2017

Ruth Ann Marrie

13

1 reference

6 September 2017

Helen Tremlett

14

1 reference

6 September 2017

British Columbia Multiple Sclerosis Clinic Neurologists

15

1 reference

6 September 2017

language of work or name

English

0 references

publication date

12 May 2017

1 reference

6 September 2017

1 reference

6 September 2017

88

1 reference

6 September 2017

24

1 reference

6 September 2017

2310-2320

1 reference

A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Risk of stroke associated with nonsteroidal anti-inflammatory drugs

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Treatment optimization in MS: Canadian MS Working Group updated recommendations.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Cytokine receptors and hematopoietic differentiation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Psychiatric side effects of interferon-beta in multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Interferon in relapsing-remitting multiple sclerosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

IFNalpha/beta promotes cell survival by activating NF-kappa B

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Neurology of the vasculitides and connective tissue diseases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Conditions that mimic stroke in the emergency department. Implications for acute stroke trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Interferon-beta mechanisms of action in multiple sclerosis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

The impact of confounder selection criteria on effect estimation

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Association between beta-interferon exposure and hospital events in multiple sclerosis.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Assessment of cancer risk with β-interferon treatment for multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Stroke after initiation of interferon-beta treatment for relapsing-remitting disseminated white matter disease.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Cardiovascular risk factors and migraine: the GEM population-based study

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Immunological aspects in migraine: increase of IL-10 plasma levels during attack

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5567323

Enhanced expression of MHC class I molecules on cultured human thyroid follicular cells infected with reovirus through induction of type 1 interferons

31 August 2018

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Musculoskeletal and systemic reactions to biological therapeutic agents

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Ten years of adverse drug reaction reports for the multiple sclerosis immunomodulatory therapies: a Canadian perspective

1 reference

12 December 2020

Validation of pharmacy records in drug exposure assessment

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

10.1212/WNL.0000000000004037

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vsve7ar7hra6bj7mguaksycobu

30 July 2022

release_vsve7ar7hra6bj7mguaksycobu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vsve7ar7hra6bj7mguaksycobu

30 July 2022

https://api.fatcat.wiki/v0/release/vsve7ar7hra6bj7mguaksycobu

1 reference

30 July 2022

https://api.fatcat.wiki/v0/release/vsve7ar7hra6bj7mguaksycobu

PubMed publication ID

1 reference

30 July 2022